Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer is a fully open access journal on tumour immunology and cancer immunotherapy founded in 2013, published by BMJ on behalf of the Society for Immunotherapy of Cancer, led since 2024 by editor-in-chief Michael T. Lotze, with a 2025 Journal Impact Factor of 11.7（Journal for ImmunoTherapy of Cancer）是 2013 年创办的肿瘤免疫学与癌症免疫治疗完全开放获取期刊，由（BMJ）代表癌症免疫治疗学会出版，自 2024 年起由（Michael T. Lotze）担任主编，2025 年影响因子为 11.7。

Scope

• It publishes high-quality research, literature reviews, position papers and practice guidelines on cancer immunology and immunotherapy该刊发表癌症免疫学与免疫治疗领域的高质量研究、文献综述、立场文件与实践指南。
• Its topics range across the basic science, translational and clinical spectrum其主题横跨基础科学、转化与临床全谱。
• It covers tumour-host interactions and the tumour microenvironment其覆盖肿瘤-宿主相互作用与肿瘤微环境。
• It also addresses animal models and predictive and prognostic immune biomarkers其亦关注动物模型以及预测性与预后性免疫生物标志物。
• It publishes work on novel pharmaceutical and cellular therapies and vaccines其发表新型药物疗法、细胞疗法与疫苗方向的研究。
• It also accepts case studies on components of cancer immunotherapy其还收录癌症免疫治疗各环节的病例研究。

History

• It was founded in 2013 as the journal of the Society for Immunotherapy of Cancer该刊于 2013 年作为癌症免疫治疗学会的官方期刊创办。
• It is published by BMJ with continuous online publication该刊由（BMJ）出版并在线连续发表。
• Michael T. Lotze and Sjoerd H. van der Burg took office as editor-in-chief and deputy editor-in-chief in 2024（Michael T. Lotze）与（Sjoerd H. van der Burg）于 2024 年就任正副主编。
• They succeeded Pedro J. Romero and James L. Gulley, who had shepherded the journal for many years他们接替长期带领该刊的（Pedro J. Romero）与（James L. Gulley）。
• Its acceptance rate is about five percent with a Journal Impact Factor of 11.7 for 2025其收稿率约 5%，2025 年影响因子为 11.7。

Editors

• Its editor-in-chief is Michael T. Lotze of the United States其主编为（Michael T. Lotze），来自美国。
• Its deputy editor-in-chief is Sjoerd H. van der Burg of the Netherlands其副主编为（Sjoerd H. van der Burg），来自荷兰。
• Its former editors-in-chief were Pedro J. Romero and James L. Gulley其前任主编为（Pedro J. Romero）与（James L. Gulley）。
• Its editorial board spans leading cancer immunotherapy centres worldwide其编委会覆盖全球主要癌症免疫治疗中心。
• Authors retain copyright and grant the journal an exclusive licence to publish作者保留版权，并授予该刊独家出版许可。